Cargando…
BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
Background: High grade serous ovarian carcinoma (HGSOC) is the most lethal type of epithelial ovarian cancer, with a prevalence of germline BRCA1/2 mutations as high as 20%. Our objective is to determine whether the location of mutations in the different domains of the BRCA1/2 genes affects the clin...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628789/ https://www.ncbi.nlm.nih.gov/pubmed/34898566 http://dx.doi.org/10.3390/curroncol28060377 |
_version_ | 1784607071541395456 |
---|---|
author | Liontos, Michalis Zografos, Eleni Zoumpourlis, Panagiotis Andrikopoulou, Angeliki Svarna, Anna Fiste, Oraianthi Kunadis, Elena Papatheodoridi, Alkistis Maria Kaparelou, Maria Koutsoukos, Konstantinos Thomakos, Nikoloas Haidopoulos, Dimitrios Rodolakis, Alexandros Dimopoulos, Meletios-Athanasios Zagouri, Flora |
author_facet | Liontos, Michalis Zografos, Eleni Zoumpourlis, Panagiotis Andrikopoulou, Angeliki Svarna, Anna Fiste, Oraianthi Kunadis, Elena Papatheodoridi, Alkistis Maria Kaparelou, Maria Koutsoukos, Konstantinos Thomakos, Nikoloas Haidopoulos, Dimitrios Rodolakis, Alexandros Dimopoulos, Meletios-Athanasios Zagouri, Flora |
author_sort | Liontos, Michalis |
collection | PubMed |
description | Background: High grade serous ovarian carcinoma (HGSOC) is the most lethal type of epithelial ovarian cancer, with a prevalence of germline BRCA1/2 mutations as high as 20%. Our objective is to determine whether the location of mutations in the different domains of the BRCA1/2 genes affects the clinical outcome of HGSOC patients. Methods: A total of 51 women with BRCA1 or BRCA2 mutated ovarian cancer were identified. Progression-free survival (PFS) and overall survival (OS) were analyzed. Results: In our study cohort, 35 patients were carriers of germline mutations in BRCA1 and 16 in BRCA2. The median PFS time following completion of the primary therapy was 23.8 months (95% CI 20.1–27.5) and the median OS was 92.9 months (95% CI 69.8–116.1) in all BRCA carriers. After multivariate analysis, no significant association among the location or type of BRCA1/2 mutation with PFS or OS was identified. Notably, significant differences in PFS between carriers of identical mutations in the same BRCA gene were detected. Conclusions: Among HGSOC patients, BRCA1/2 carriers with mutations in different locations of the genes show no significant difference in survival outcomes, in terms of PFS and OS, suggesting the potential effect of other genetic abnormalities and co-contributing risk factors. |
format | Online Article Text |
id | pubmed-8628789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86287892021-11-30 BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients Liontos, Michalis Zografos, Eleni Zoumpourlis, Panagiotis Andrikopoulou, Angeliki Svarna, Anna Fiste, Oraianthi Kunadis, Elena Papatheodoridi, Alkistis Maria Kaparelou, Maria Koutsoukos, Konstantinos Thomakos, Nikoloas Haidopoulos, Dimitrios Rodolakis, Alexandros Dimopoulos, Meletios-Athanasios Zagouri, Flora Curr Oncol Article Background: High grade serous ovarian carcinoma (HGSOC) is the most lethal type of epithelial ovarian cancer, with a prevalence of germline BRCA1/2 mutations as high as 20%. Our objective is to determine whether the location of mutations in the different domains of the BRCA1/2 genes affects the clinical outcome of HGSOC patients. Methods: A total of 51 women with BRCA1 or BRCA2 mutated ovarian cancer were identified. Progression-free survival (PFS) and overall survival (OS) were analyzed. Results: In our study cohort, 35 patients were carriers of germline mutations in BRCA1 and 16 in BRCA2. The median PFS time following completion of the primary therapy was 23.8 months (95% CI 20.1–27.5) and the median OS was 92.9 months (95% CI 69.8–116.1) in all BRCA carriers. After multivariate analysis, no significant association among the location or type of BRCA1/2 mutation with PFS or OS was identified. Notably, significant differences in PFS between carriers of identical mutations in the same BRCA gene were detected. Conclusions: Among HGSOC patients, BRCA1/2 carriers with mutations in different locations of the genes show no significant difference in survival outcomes, in terms of PFS and OS, suggesting the potential effect of other genetic abnormalities and co-contributing risk factors. MDPI 2021-11-03 /pmc/articles/PMC8628789/ /pubmed/34898566 http://dx.doi.org/10.3390/curroncol28060377 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liontos, Michalis Zografos, Eleni Zoumpourlis, Panagiotis Andrikopoulou, Angeliki Svarna, Anna Fiste, Oraianthi Kunadis, Elena Papatheodoridi, Alkistis Maria Kaparelou, Maria Koutsoukos, Konstantinos Thomakos, Nikoloas Haidopoulos, Dimitrios Rodolakis, Alexandros Dimopoulos, Meletios-Athanasios Zagouri, Flora BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients |
title | BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients |
title_full | BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients |
title_fullStr | BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients |
title_full_unstemmed | BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients |
title_short | BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients |
title_sort | brca1/2 mutation types do not affect prognosis in ovarian cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628789/ https://www.ncbi.nlm.nih.gov/pubmed/34898566 http://dx.doi.org/10.3390/curroncol28060377 |
work_keys_str_mv | AT liontosmichalis brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT zografoseleni brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT zoumpourlispanagiotis brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT andrikopoulouangeliki brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT svarnaanna brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT fisteoraianthi brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT kunadiselena brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT papatheodoridialkistismaria brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT kapareloumaria brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT koutsoukoskonstantinos brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT thomakosnikoloas brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT haidopoulosdimitrios brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT rodolakisalexandros brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT dimopoulosmeletiosathanasios brca12mutationtypesdonotaffectprognosisinovariancancerpatients AT zagouriflora brca12mutationtypesdonotaffectprognosisinovariancancerpatients |